MGNX logo

MacroGenics, Inc.

MGNX

MGNX: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

more

Show MGNX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MGNX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MGNX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Tri-specific binding molecules that specifically bind to multiple cancer antigens Jul. 11, 2023
  • Patent Title: Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof May. 02, 2023
  • Patent Title: Pd-1-binding molecules and methods of use thereof Apr. 11, 2023
  • Patent Title: B7-h3 directed antibody drug conjugates Feb. 28, 2023
  • Patent Title: Pharmaceutical compositions of a her2/neu antibody and use of the same Oct. 04, 2022
  • Patent Title: Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof Oct. 04, 2022
  • Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Aug. 23, 2022
  • Patent Title: Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof Jul. 12, 2022
  • Patent Title: Covalent diabodies and uses thereof Feb. 22, 2022
  • Patent Title: Covalent diabodies and uses thereof Feb. 22, 2022
  • Patent Title: Adam9-binding molecules, and methods of use thereof Feb. 08, 2022
  • Patent Title: Combination therapy for the treatment of cancer Nov. 16, 2021
  • Patent Title: Cd3-binding molecules capable of binding to human and non-human cd3 Sep. 07, 2021
  • Patent Title: Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof Aug. 24, 2021
  • Patent Title: Fcγriib-specific antibodies and methods of use thereof Aug. 24, 2021
  • Patent Title: Combination therapy for the treatment of cancer Aug. 03, 2021
  • Patent Title: Lag-3-binding molecules and methods of use thereof Jul. 27, 2021
  • Patent Title: Her2/neu-specific antibodies and methods of using same Jun. 08, 2021
  • Patent Title: B7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof Mar. 30, 2021
  • Patent Title: Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof Mar. 23, 2021
  • Patent Title: Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof Dec. 08, 2020
  • Patent Title: Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof Sep. 29, 2020
  • Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Aug. 04, 2020
  • Patent Title: Antibodies reactive with b7-h3 and users thereof Aug. 04, 2020
  • Patent Title: Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcγr Jul. 14, 2020
  • Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Jun. 16, 2020
  • Patent Title: Multi-chain polypeptide-containing tri-specific binding molecules May. 12, 2020
  • Patent Title: Pd-1-binding molecules and methods of use thereof Mar. 03, 2020
  • Patent Title: Multivalent molecules comprising dr5-binding domains Dec. 10, 2019
  • Patent Title: Bcr-complex-specific antibodies and methods of using same Nov. 19, 2019
  • Patent Title: Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof Jul. 09, 2019
  • Patent Title: Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof Dec. 25, 2018
  • Patent Title: Cd3-binding molecules capable of binding to human and non-human cd3 Dec. 11, 2018
  • Patent Title: Her2/neu-specific antibodies and methods of using same Nov. 20, 2018
  • Patent Title: Methods for the treatment of vascularizing cancers Oct. 16, 2018
  • Patent Title: Fcγriib-specific antibodies and methods of use thereof Oct. 16, 2018
  • Patent Title: Covalent diabodies and uses thereof Oct. 09, 2018
  • Patent Title: Covalent diabodies and uses thereof Oct. 09, 2018
  • Patent Title: Covalent diabodies and uses thereof May. 08, 2018
  • Patent Title: Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof Apr. 03, 2018
  • Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Mar. 06, 2018
  • Patent Title: Antibodies reactive with b7-h3 and uses thereof Feb. 20, 2018
  • Patent Title: Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin Feb. 13, 2018
  • Patent Title: Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof Nov. 21, 2017
  • Patent Title: Combination of fcγriib-specific antibodies and cd20-specific antibodies and methods of use thereof Aug. 22, 2017
  • Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Jul. 25, 2017
  • Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Jul. 25, 2017
  • Patent Title: Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcγr Jul. 18, 2017
  • Patent Title: Bcr-complex-specific antibodies and methods of using same Jul. 04, 2017
  • Patent Title: Cd3-binding molecules capable of binding to human and non-human cd3 Mar. 07, 2017
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of MGNX in WallStreetBets Daily Discussion

MGNX News

Recent insights relating to MGNX

CNBC Recommendations

Recent picks made for MGNX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MGNX

Corporate Flights

Flights by private jets registered to MGNX